{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000023","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.590572+00:00","generated_at":"2026-06-17T05:01:32.286088+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"AnaptysBio director Laura Hamill resigns; Rita Jain appointed to board and compensation committee","bullets":["Laura J. Hamill resigned as Class II director effective April 1, 2023; no disagreement with company.","Rita Jain, M.D. appointed as Class II director and Compensation Committee member effective April 3, 2023.","Jain receives pro-rata annual retainer: option for 8,015 shares at April 3 closing price, 3,234 RSUs vesting at 2024 annual meeting.","Additional grants: option for 10,600 shares and 3,900 RSUs, each vesting over three years."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000023","json":"https://secwatch.observer/filing/0001370053-23-000023.json","markdown":"https://secwatch.observer/filing/0001370053-23-000023.md","text":"https://secwatch.observer/filing/0001370053-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000023/0001370053-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000023/anab-20230401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:01:32.286088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bd8c52e56","claim":"Rita Jain was appointed as Class II director and member of Compensation Committee at ANAPTYSBIO, INC.","evidence_excerpt":"On April 3, 2023, the Board appointed Rita Jain, M.D. as a Class II director and as a member of the Compensation Committee, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000023/0001370053-23-000023-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director and member of Compensation Committee"}],"fact_type":"executive_change"},{"claim_id":"d5c4375527","claim":"Laura J. Hamill resigned as Class II director at ANAPTYSBIO, INC.","evidence_excerpt":"On April 1, 2023, Laura J. Hamill advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that she would resign as a Class II director of the Board, effective on April 1, 2023 (the “ Resignation ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000023/0001370053-23-000023-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}